# Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

> **NCT06700798** · PHASE2 · RECRUITING · sponsor: **Fei Li** · enrollment: 90 (estimated)

## Conditions studied

- Marginal Zone Lymphoma(MZL)

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisone tablet

## Key facts

- **NCT ID:** NCT06700798
- **Lead sponsor:** Fei Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-05-04
- **Final completion:** 2027-12-04
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06700798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06700798, "Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06700798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*